Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

 
• By Emily Hayes

In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.

Bristol’s IO Pathways In Development
Bristol is developing many new immuno-oncology mechanisms, some of which were showcased at the SITC meeting in November. • Source: Bristol-Myers Squibb

More from Immuno-oncology

More from Anticancer